Aurobindo Pharma to expand product portfolio in the US

08 Jun 2017 Evaluate

Aurobindo Pharma is expanding its product portfolio in the US with high-value drugs. The portfolio mix is complemented with the introduction of high-value products and the future pipeline will include oncology, hormones, depot injections, inhalers, biosimilars, patches and films.

The addressable market for the company’s total 429 Abbreviated New Drug Applications (ANDAs) has been pegged at $91 billion, including $61 billion for the ANDAs which are under review and tentatively approved.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1134.70 31.15 (2.82%)
26-Apr-2024 13:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1503.45
Dr. Reddys Lab 6272.25
Cipla 1408.80
Zydus Lifesciences 947.45
Lupin 1616.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.